UNC School of Medicine researchers led by Brian Conlon, PhD, discover how molecules called rhamnolipids could make common aminoglycoside antibiotics effective against the toughest Staph infections.
Staphylococcus aureus bacteria are a major cause of serious infections that often persist despite antibiotic treatment, but scientists at the UNC School of Medicine have now discovered a way to make these bacteria much more susceptible to some common antibiotics.
The scientists, in a study published in Cell Chemical Biology, found that adding molecules called rhamnolipids can make aminoglycoside antibiotics, such as tobramycin, hundreds of times more potent against S. aureus – including the strains that are otherwise very hard to kill. The rhamnolipids effectively loosen up the outer membranes of S. aureus cells so that aminoglycoside molecules can get into them more easily.
“There’s a great need for new ways to kill bacteria that tolerate or resist standard antibiotics, and to that end we found that altering membrane permeability to induce aminoglycoside uptake is an extremely effective strategy against S. aureus,” said study senior author Brian Conlon, PhD, an assistant professor in the department of microbiology and immunology at the UNC School of Medicine.
The U.S. Centers for Disease Control has estimated that in 2017 there were more than 119,000 cases of serious bloodstream Staph infections in the United States, of which more than 20,000 were fatal.
Standard treatments for many strains of the S. aureus do not kill the bacteria, either because the bacteria have genetically acquired specific antibiotic resistance or because they grow in the body in a way that makes them inherently less vulnerable. For example, S. aureus can adapt its metabolism to survive in low-oxygen zones in abscesses or in the mucus-filled lungs of people with cystic fibrosis. In these environments, the bacterial outer wall or membrane becomes relatively impermeable to aminoglycosides, such as tobramycin.
Conlon and colleagues, including first author Lauren Radlinski, a PhD candidate in the Conlon laboratory, found in a 2017 study that rhamnolipids greatly enhance tobramycin’s potency against standard test strains of S. aureus. Rhamnolipids are small molecules produced by another bacterial species, Pseudomonas aeruginosa, and are thought to be one of P. aeruginosa’s natural weapons against other bacteria in the wild. At high doses they make holes in rival bacteria’s cell membranes. The UNC researchers found that rhamnolipids greatly boost the uptake of tobramycin molecules, even at low doses where they have no independent anti-bacterial effect.
In the new study, Conlon, Radlinski and colleagues tested rhamnolipid-tobramycin combinations against S. aureus populations that are particularly hard to kill in ordinary clinical practice. The researchers found that rhamnolipids boost tobramycin’s potency against:
• S. aureus growing in low-oxygen niches;
• MRSA (methicillin-resistant S. aureus), which are a family of dangerous S. aureus variants with genetically acquired treatment resistance;
• tobramycin-resistant S. aureus strains isolated from cystic fibrosis patients;
• and “persister” forms of S. aureus that normally have reduced susceptibility to antibiotics because they grow so slowly.
Radlinski said, “Tobramycin doses that normally would have little or no effect on these S. aureus populations quickly killed them when combined with rhamnolipids.”
Conlon, Radlinski, and colleagues determined that rhamnolipids even at low doses alter the S. aureusmembrane in a way that makes it much more permeable to aminoglycosides. Each antibiotic in this family that they tested – including tobramycin, gentamicin, amikacin, neomycin, and kanamycin – had its potency enhanced. The experiments showed, moreover, that this potency-boosting strategy is effective not just against S. aureus but several other bacterial species, including Clostridioides difficile (C-diff), which is a major cause of serious, often-fatal diarrheal illness among the elderly and patients in hospitals.
Rhamnolipids come in many variants, and the scientists now hope to determine if there is an optimal variant that works powerfully against other bacteria while having little or no toxic effect on human cells. The team also plans to study other microbe-vs.-microbe weapons to find new ways to enhance the potency of existing antibiotics.
“There’s a huge number of bacterial interspecies interactions that could be influencing how well our antibiotics work,” Radlinski said. “We aim to find them with the ultimate goal of improving the efficacy of current therapeutics and slowing the rise of antibiotic resistance.”
The Latest on: Antibiotic resistance
via Google News
The Latest on: Antibiotic resistance
- Glaxo launches late-stage development of antibiotic gepotidacinon October 28, 2019 at 10:36 am
The two clinical trials will evaluate the drug in the two infections cited above caused by bacteria that the CDC has identified as antibiotic resistance threats. EAGLE 1 will compare gepotidacin to ...
- GlaxoSmithKline starts late-stage trial for experimental antibioticon October 28, 2019 at 4:11 am
The antibiotic, gepotidacin, is the first of a new class of drugs and is expected to treat two common bacterial infections, which have been identified as antibiotic resistant threats by U.S. health ...
- New Technique Helps Researchers Understand How Bacteria Become Antibiotic Resistanton October 28, 2019 at 3:51 am
This allows the bacteria to acquire new genetic traits and functions. The process is how bacteria becomes resistant to antibiotics. Jennifer Chlebek is a Ph.D. student who led the study. She says the ...
- Sewage, rivers and soils provide missing link in antibiotic resistance storyon October 28, 2019 at 3:04 am
We ask you to do this by linking back to our original story. HTML for this article, including the attribution and page view counter, is below: Sewage, rivers and soils provide missing link in ...
- Research: People Not Washing Hands After Using Toilet Is Behind Spread Of Antibiotic-Resistant E. Colion October 26, 2019 at 10:14 am
(CNN) — People failing to wash their hands after going to the toilet, rather than undercooked meat or other food, is behind the spread of antibiotic-resistant E. coli, according to new research.
- Multi Drug Resistant Antibiotics market Opportunities, Competitive Benchmarking and Forecast To 2025on October 24, 2019 at 10:04 pm
Oct 25, 2019 (WiredRelease via COMTEX) -- The latest report, Multi Drug Resistant Antibiotics market attempts to explain as well as understand the buying pattern to help companies design a marketing ...
- New diagnostic tools are essential in the battle against antibiotic resistanceon October 24, 2019 at 2:06 am
A century ago, a severe bacterial infection was often a death sentence. With the advent of penicillin and the antibiotics that followed, such infections became eminently manageable, even routine.
- Common meds alter microbiome, increase antibiotic resistance riskon October 23, 2019 at 6:46 am
Oct. 23 --Some widely used drugs alter the population of microbes in the gut, and a number raise the risk of antibiotic resistance, a new Dutch study shows. The gut microbiome includes at least 1,000 ...
- Bacterial lifestyle alters the evolution of antibiotic resistanceon October 23, 2019 at 12:53 am
How bacteria live—whether as independent cells or in a communal biofilm—determines how they evolve antibiotic resistance, which could lead to more personalized approaches to antimicrobial therapy and ...
- Oh, good: An antibiotic-resistant germ evolved to beat a ‘last resort’ drug in less than a monthon October 22, 2019 at 8:13 pm
Antibiotics are great, but one of the biggest fears of medical experts and researchers has been the emergence of so-called “superbugs,” or antibiotic-resistant bacteria that mutate to defend against ...
via Bing News